Video: How To Efficiently Patch A Medtech Regulatory System ‘Set Up To Fail’

“Hindsight is a wonderful thing, but foresight is better.”

Centralization and rationalization of the EU’s medtech rules are critical, particularly for conformity assessment and clinical evidence. Hear the views of Tom Melvin and Erik Vollebregt first-hand in a new in-depth interview on regulatory problems and opportunities.

Vodcast: How To Efficiently Patch A Medtech Regulatory System ‘Set Up To Fail’
Building Onto The EU's Medtech Regulations To Finish A Job Started But Not Completed

In this video interview with Medtech Insight, clinician and academic Tom Melvin, and legal medtech expert Erik Vollebregt expose the underlying regulatory factors that are undermining medical device safety efforts and damaging continued availability of medical devices in the EU.

Their strong opinions accord over what is now needed to fix the EU’s problematic medtech regulatory system.

Neither expert shy away from giving strong opinions about elements that urgently need correcting within the system.

But they also offer solutions that should be relatively easy to accommodate within the current EU rules, including introducing more reproducibility of efforts within the system to make it more efficient.

Deep Dive Into The Challenges

Topics covered during the interview include: role of competent authorities, notified bodies and expert panels; centralized regulatory control in the EU; clinical evidence; clinical standardization; “over-proceduralizing” of regulations; the regulation of high-risk devices versus other devices; creating EU-wide regulatory rationalization and efficiency; and the EU’s role in international harmonization.

Melvin, as associate professor of Medical Device Regulatory Affairs at Trinity College Dublin, gives particularly pertinent insights related to historic regulatory examples, including what has happened with medicines and how the US medtech system has evolved. And as a former clinician, he delivers valuable insights into the challenges that clinicians experience with medical devices on a day-to-day basis.

Vollebregt, a life sciences specialist lawyer and medtech regulatory expert at Axon Lawyers in the Netherlands, is at the forefront of promoting medtech regulatory change, having in summer 2024 helped draft the initiative for amendments to the MDR developed by MEP Peter Liese. (Also see "How The European Parliament Seeks To Amend The MDR: A Step-By-Step Guide" - Medtech Insight, 4 June, 2024.)

The quotes below offer highlights of the conversation and an indication of the topics covered and approach taken. But to do justice to the depth of this discussion featuring two of the EU’s most impactful regulatory voices on the fundamental challenges and needs of the EU regulatory system, readers can access the whole video interview via the link above.

Moreover, to help navigate your way around the interview, timestamps are provided alongside the quotes.

More from Europe

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Bates To Energize UK Office For Life Sciences

 
• By 

Steve Bates, head of the UK BioIndustry Association, has been appointed executive chair of the government’s Office for Life Sciences as the UK restructures its life sciences approach and drives health outcomes with a new NHS Long-Term Care plan.

International Reliance Gets UK MHRA OK In Drive For Agile Pre-Market Regulation – CE Marking Next

 
• By 

The UK government’s response to MHRA public consultation on risk proportionate device routes to market and physical UKCA markings adds momentum to drive for modern, agile system. Another consultation in late 2025 will propose indefinite recognition of CE-marked devices in Great Britain.

Expert Panels Remain Tough On Manufacturers And Their Notified Bodies

 

The EU’s extra layer of checks on clinical evidence is proving a difficult, and sometimes humiliating process, for many device companies whose products have come under the spotlight.

More from Geography

Time For Medtech To Have Its Say On Critical Changes In EU Framework Legislation

 

In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.

Medtech M&A Resurges: How To Define Startup Exit Strategy

 

The medtech M&A landscape is experiencing a resurgence fueled by significant capital from private equity and venture firms, says Alex Wakefield, CRO of AcuityMD. Building strong relationships with physicians remains crucial in medtech, and defining an exit strategy early is imperative.

HHS Suggests Drastic Reductions To Skin Substitute Payments

 
• By 

The US Department of Health and Human Services has proposed cutting Medicare reimbursement for skin substitutes used in chronic wound care by up to 90%. The change aims to address rising costs but could harm patient access and treatment quality, prompting concerns from industry stakeholders.